A persistent neutrophil-associated immune signature characterizes post-COVID-19 pulmonary sequelae
Interstitial lung disease and associated fibrosis occur in a proportion of individuals who have recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection through unknown mechanisms. We studied individuals with severe coronavirus disease 2019 (COVID-19) after recovery from acute illness. Individuals with evidence of interstitial lung changes at 3 to 6 months after recovery had an up-regulated neutrophil-associated immune signature including increased chemokines, proteases, and markers of neutrophil extracellular traps that were detectable in the blood. Similar pathways were enriched in the upper airway with a concomitant increase in antiviral type I interferon signaling. Interaction analysis of the peripheral phosphoproteome identified enriched kinases critical for neutrophil inflammatory pathways. Evaluation of these individuals at 12 months after recovery indicated that a subset of the individuals had not yet achieved full normalization of radiological and functional changes. These data provide insight into mechanisms driving development of pulmonary sequelae during and after COVID-19 and provide a rational basis for development of targeted approaches to prevent long-term complications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Science translational medicine - 14(2022), 671 vom: 16. Nov., Seite eabo5795 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
George, Peter M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 18.11.2022 Date Revised 14.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1126/scitranslmed.abo5795 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348970838 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348970838 | ||
| 003 | DE-627 | ||
| 005 | 20240214232615.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1126/scitranslmed.abo5795 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1292.xml |
| 035 | |a (DE-627)NLM348970838 | ||
| 035 | |a (NLM)36383686 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a George, Peter M |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A persistent neutrophil-associated immune signature characterizes post-COVID-19 pulmonary sequelae |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.11.2022 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Interstitial lung disease and associated fibrosis occur in a proportion of individuals who have recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection through unknown mechanisms. We studied individuals with severe coronavirus disease 2019 (COVID-19) after recovery from acute illness. Individuals with evidence of interstitial lung changes at 3 to 6 months after recovery had an up-regulated neutrophil-associated immune signature including increased chemokines, proteases, and markers of neutrophil extracellular traps that were detectable in the blood. Similar pathways were enriched in the upper airway with a concomitant increase in antiviral type I interferon signaling. Interaction analysis of the peripheral phosphoproteome identified enriched kinases critical for neutrophil inflammatory pathways. Evaluation of these individuals at 12 months after recovery indicated that a subset of the individuals had not yet achieved full normalization of radiological and functional changes. These data provide insight into mechanisms driving development of pulmonary sequelae during and after COVID-19 and provide a rational basis for development of targeted approaches to prevent long-term complications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Reed, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Desai, Sujal R |e verfasserin |4 aut | |
| 700 | 1 | |a Devaraj, Anand |e verfasserin |4 aut | |
| 700 | 1 | |a Faiez, Tasnim Shahridan |e verfasserin |4 aut | |
| 700 | 1 | |a Laverty, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Kanwal, Amama |e verfasserin |4 aut | |
| 700 | 1 | |a Esneau, Camille |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Michael K C |e verfasserin |4 aut | |
| 700 | 1 | |a Kamal, Faisal |e verfasserin |4 aut | |
| 700 | 1 | |a Man, William D-C |e verfasserin |4 aut | |
| 700 | 1 | |a Kaul, Sundeep |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Suveer |e verfasserin |4 aut | |
| 700 | 1 | |a Lamb, Georgia |e verfasserin |4 aut | |
| 700 | 1 | |a Faizi, Fatima K |e verfasserin |4 aut | |
| 700 | 1 | |a Schuliga, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Read, Jane |e verfasserin |4 aut | |
| 700 | 1 | |a Burgoyne, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Pinto, Andreia L |e verfasserin |4 aut | |
| 700 | 1 | |a Micallef, Jake |e verfasserin |4 aut | |
| 700 | 1 | |a Bauwens, Emilie |e verfasserin |4 aut | |
| 700 | 1 | |a Candiracci, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Bougoussa, Mhammed |e verfasserin |4 aut | |
| 700 | 1 | |a Herzog, Marielle |e verfasserin |4 aut | |
| 700 | 1 | |a Raman, Lavanya |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmetaj-Shala, Blerina |e verfasserin |4 aut | |
| 700 | 1 | |a Turville, Stuart |e verfasserin |4 aut | |
| 700 | 1 | |a Aggarwal, Anupriya |e verfasserin |4 aut | |
| 700 | 1 | |a Farne, Hugo A |e verfasserin |4 aut | |
| 700 | 1 | |a Dalla Pria, Alessia |e verfasserin |4 aut | |
| 700 | 1 | |a Aswani, Andrew D |e verfasserin |4 aut | |
| 700 | 1 | |a Patella, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Borek, Weronika E |e verfasserin |4 aut | |
| 700 | 1 | |a Mitchell, Jane A |e verfasserin |4 aut | |
| 700 | 1 | |a Bartlett, Nathan W |e verfasserin |4 aut | |
| 700 | 1 | |a Dokal, Arran |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Xiao-Ning |e verfasserin |4 aut | |
| 700 | 1 | |a Kelleher, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Anand |e verfasserin |4 aut | |
| 700 | 1 | |a Singanayagam, Aran |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Science translational medicine |d 2009 |g 14(2022), 671 vom: 16. Nov., Seite eabo5795 |w (DE-627)NLM195151879 |x 1946-6242 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:671 |g day:16 |g month:11 |g pages:eabo5795 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1126/scitranslmed.abo5795 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 671 |b 16 |c 11 |h eabo5795 | ||